Ones To Watch News
Refine Search
Biotechnology
US clinical-stage biotech Magenta Therapeutics has halted dosing in one of the groups taking part in a Phase I/II study of cancer candidate MGTA-117. 21 December 2022
Biotechnology
US biotech major Gilead Science today revealed that its Kite subsidiary has reached agreement to acquire privately-held Tmunity Therapeutics, a start-up set up by Carl June and his colleagues at the University of Pennsylvania and with former Novartis heavyweight Usman ‘Oz’ Azam as chief executive. 20 December 2022
Biotechnology
Californian companies Gilead Sciences and Arcus Biosciences have announced positive results from the fourth interim analysis of the ARC-7 study. 20 December 2022
Pharmaceutical
Ireland-based cancer focused biopharma Carrick Therapeutics and family-owned Italian pharma Menarini have announced a clinical trial collaboration and supply agreement. 20 December 2022
Pharmaceutical
Switzerland-based Idorsia today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, the firm’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with difficult-to-control hypertension. 20 December 2022
Pharmaceutical
Shares of Pennsylvania, USA-based liver disease specialist Madrigal Pharmaceuticals skyrocketed 270% to $227.90 after reporting success in non-alcoholic steatohepatitis (NASH), a therapy sector that so far has been littered with disappointments. 19 December 2022
Biotechnology
Clinical-stage US biotech Mustang Biotech, which is focused on cell and gene therapies for hematologic cancers, solid tumors and rare genetic diseases, today provided updates on its CAR-T portfolio and 2023 anticipated milestones. 19 December 2022
Biotechnology
The European Commission (EC) has granted marketing authorization for Ebvallo (tabelecleucel)vas a monotherapy for treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein Barr virus positive post transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. 19 December 2022
Biotechnology
Shares of Innate Pharma were almost 14% higher at 2.34 euros by late morning on the news that it has expanded its collaboration with fellow France-based pharma major Sanofi. 19 December 2022
Pharmaceutical
Cratering shares in Cambridge, Massachusetts-based inflammatory disease company Third Harmonic Bio reflect a loss in confidence after a Phase I failure. 16 December 2022
Biotechnology
Pennsylvania, USA-based CNS specialist Vallon Pharmaceuticals’ stock price soared an initial 230% to $0.85, after the company unveiled plans to merge its operations with privately-held biotech GRI Bio in an all-stock transaction. 15 December 2022
Biotechnology
US RNA company Avidity Biosciences closed 55% higher following Wednesday’s trading. 15 December 2022
Biotechnology
A Danish company developing a vaccine against group B streptococcus (GBS) - an infection often known as Strep B - has 72 million ($77 million) euros more to spend. 15 December 2022
Biotechnology
French drug resistance specialist Ribonexus has appointed Steven Powell as chief executive, as the company prepares to seek more financing for its small molecule programs. 14 December 2022
Biotechnology
US clinical stage biotech Praxis Precision Medicines’ shares closed up nearly 5% yesterday and rose a further 2.3% to $2.25 pre-market, on the news of a strategic collaboration with Belgium’s UCB, based on Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies. 14 December 2022
Biotechnology
The retiring Paul Perreault is to be replaced by another Paul as chief executive and managing director of Australian biotech CSL Limited. 13 December 2022
Pharmaceutical
Providing further evidence that generics major Viatris is pushing wider beyond copy drugs, the company has entered into an exclusive license agreement with Sweden’s Calliditas Therapeutics to register and commercialize the latter’s Nefecon in Japan. 13 December 2022
Biotechnology
Troubled US biotech Clovis Oncology has officially filed for bankruptcy in Delaware, hit by a fall in its cancer drug sales and challenges in raising additional capital, and will also seek to sell its assets through a court supervised sales process. 13 December 2022
Biotechnology
A second KRAS blocker has won US approval, opening further a market in oncology based on a target that was once thought undruggable. 13 December 2022
Biotechnology
Coming as no surprise following rumors for the last couple of weeks, but with a much bigger price tag than had been expected, US biotech giant Amgen today announced that it is to acquire Horizon Therapeutics. 12 December 2022
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze